I have a feeling we start the week UP!
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
I have a feeling we start the week UP!
Tamiflu is in short supply. This is close to baby formula problem out of ABT.
Lots and lots of people are sick heading into Thanksgiving. We know a bunch.
There is no more real funding coming from congress for any of this so we must look at what is in the works or already out there.
Now MGNX is ours and why we like it is they are getting $$$'s for the Provention product! The ole' back door...
Provention Bio's type 1 diabetes drug Tzield priced at ~$14K per vial-- now that pricing is revealed Provention should run!
Nov. 18, 2022 1:23 PM ETMGNX, PRVB
So A) This is not here's three extra months... Lots of Drugs don't really extend disease free progression that long this does! That's importinat.
Also we are talking Pre stage 1... living 2 -11 years without needing meds for the condition.
AND those who already have Diabetes- the stage 2 to stage 3 is an important milestone you want to delay.
So we have multiple indications $
We have ongoing trials that keep getting better $
We are the only game in town $
It is for these reasons we are willing to overlook the hospital setting for treatment and price etc.
"The progression of T1D can be particularly onerous; patients who progress from Stage 2 to Stage 3 T1D can develop diabetic ketoacidosis, which can be life threatening and is experienced by up to 50% of Stage 3 patients at the time of presentation. The onset of Stage 3 T1D is a life-changing moment - once insulin-producing cells are no longer capable of maintaining normal glycemic control, this irreversible condition can lead to the need, in just one year, for a patient, 1,460 finger sticks to check blood glucose levels, around 1,100 insulin injections, and experiencing an average of 127 episodes of hypoglycemia. These complications can cause stress, fear, and anxiety in patients as they work to manage their T1D diagnosis and provide perspective on the meaning of a delay in the onset of Stage 3 T1D." notes Dr.Eleanor Ramos, Chief Medical Officer at Provention Bio. "As described in the approved label, TZIELD binds to CD3 (a cell surface antigen present on T lymphocytes) and its mechanism is believed to involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. TZIELD leads to an increase in the proportion of regulatory T cells and exhausted CD8+ T cells in peripheral blood."
Lots and lots of people are sick heading into Thanksgiving. We know a bunch.
There is no more real funding coming from congress for any of this so we must look at what is in the works or already out there.
Now MGNX is ours and why we like it is they are getting $$$'s for the Provention product! The ole' back door...
Provention Bio's type 1 diabetes drug Tzield priced at ~$14K per vial-- now that pricing is revealed Provention should run!
Nov. 18, 2022 1:23 PM ETMGNX, PRVB
- A day after receiving approval for type 1 diabetes medication Tzield (tewplizumab), Provention Bio (PRVB) priced the biologic at $13,850 per vial.
- Dosing for Tzield is a daily infusion for 14 consecutive days.
- MacroGenics (MGNX) will get a $60M milestone paymentfrom Provention Bio (PRVB) due to Tzield's approval.
So A) This is not here's three extra months... Lots of Drugs don't really extend disease free progression that long this does! That's importinat.
Also we are talking Pre stage 1... living 2 -11 years without needing meds for the condition.
AND those who already have Diabetes- the stage 2 to stage 3 is an important milestone you want to delay.
So we have multiple indications $
We have ongoing trials that keep getting better $
We are the only game in town $
It is for these reasons we are willing to overlook the hospital setting for treatment and price etc.
"The progression of T1D can be particularly onerous; patients who progress from Stage 2 to Stage 3 T1D can develop diabetic ketoacidosis, which can be life threatening and is experienced by up to 50% of Stage 3 patients at the time of presentation. The onset of Stage 3 T1D is a life-changing moment - once insulin-producing cells are no longer capable of maintaining normal glycemic control, this irreversible condition can lead to the need, in just one year, for a patient, 1,460 finger sticks to check blood glucose levels, around 1,100 insulin injections, and experiencing an average of 127 episodes of hypoglycemia. These complications can cause stress, fear, and anxiety in patients as they work to manage their T1D diagnosis and provide perspective on the meaning of a delay in the onset of Stage 3 T1D." notes Dr.Eleanor Ramos, Chief Medical Officer at Provention Bio. "As described in the approved label, TZIELD binds to CD3 (a cell surface antigen present on T lymphocytes) and its mechanism is believed to involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. TZIELD leads to an increase in the proportion of regulatory T cells and exhausted CD8+ T cells in peripheral blood."
You mean the one I got us 150K views on?
Looks like Elon has re-instated Trump's TWTR account.
Stoney in drag:
-BUY Provention Bio- $8.05
and you should already have MGNX!<-- Robin Hood will get a whiff.// I shall tell them. I believe MGNX will be the big winner. And yet another GBA double!!!!
Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October.
MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018. As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.
closed the third quarter with $123.6 million in cash, then received another $60 million from Gilead Sciences Inc. (NASDAQ: GILD) in October as part of a new collaboration agreement.That deal, for Gilead to develop and exclusively license MacroGenics’ blood cancer treatment candidate MGD024, could drive more than $1.7 billion to the local company over time.
The $60 million from Provention along with other expected payments from partners should extend MacroGenics’ cash runway into late 2024, the company said Thursday.
“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” Scott Koenig, president and CEO of MacroGenics, said in a statement. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of Type 1 diabetes.”
The payment follows a corporate restructuring in August, when MacroGenics reduced its workforce by 15% and closed two facilities to help repurpose funds for research and development of key cancer treatment candidates. “All of these cost-saving measures are proceeding according to plan,” Koenig said earlier this month on a third-quarter company earnings call.
MacroGenics reported $78.8 million in revenue for the first nine months of 2022, up from $63.3 million for the first nine months of 2021. The business shaved its net loss in the third quarter of 2022 to $24.8 million, from $52.9 million in the third quarter of 2021.
The company is advancing multiple clinical trials, including a study of a treatment in prostate cancer set to begin before year’s end. It’s also continuing a trial of treatment candidate lorigerlimab in colorectal cancer, a form of advanced prostate cancer, melanoma and a type of nonsmall cell lung cancer. That’s set to report data in the first quarter of the new year.
Great areas to target!
and you should already have MGNX!<-- Robin Hood will get a whiff.// I shall tell them. I believe MGNX will be the big winner. And yet another GBA double!!!!
Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October.
MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018. As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.
closed the third quarter with $123.6 million in cash, then received another $60 million from Gilead Sciences Inc. (NASDAQ: GILD) in October as part of a new collaboration agreement.That deal, for Gilead to develop and exclusively license MacroGenics’ blood cancer treatment candidate MGD024, could drive more than $1.7 billion to the local company over time.
The $60 million from Provention along with other expected payments from partners should extend MacroGenics’ cash runway into late 2024, the company said Thursday.
“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” Scott Koenig, president and CEO of MacroGenics, said in a statement. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of Type 1 diabetes.”
The payment follows a corporate restructuring in August, when MacroGenics reduced its workforce by 15% and closed two facilities to help repurpose funds for research and development of key cancer treatment candidates. “All of these cost-saving measures are proceeding according to plan,” Koenig said earlier this month on a third-quarter company earnings call.
MacroGenics reported $78.8 million in revenue for the first nine months of 2022, up from $63.3 million for the first nine months of 2021. The business shaved its net loss in the third quarter of 2022 to $24.8 million, from $52.9 million in the third quarter of 2021.
The company is advancing multiple clinical trials, including a study of a treatment in prostate cancer set to begin before year’s end. It’s also continuing a trial of treatment candidate lorigerlimab in colorectal cancer, a form of advanced prostate cancer, melanoma and a type of nonsmall cell lung cancer. That’s set to report data in the first quarter of the new year.
Great areas to target!
Van! Twitter is going to crash during the soccer cup. >
Advertisers are all leaving >
Musk is turning out to be a big dumb dumb.>
His own accountants are furious. >
This little folly will end up costing him maybe a billion! >
I don't get it. Never have. And have never ever been on Twitter.
Maybe it's great but why risk everything and buy it? I don't get it.
Advertisers are all leaving >
Musk is turning out to be a big dumb dumb.>
His own accountants are furious. >
This little folly will end up costing him maybe a billion! >
I don't get it. Never have. And have never ever been on Twitter.
Maybe it's great but why risk everything and buy it? I don't get it.
You mean the one I got us 150K views on?
Van I hate to bust your bubble and nobody loves Van more than me that's a fact.
But the thread has over 20K unique viewers many of them professionals in the stock world. I have sent the link around to major house and hedge funds. We are viewed by the most upper upper parts of the financial system. Even the head of one of the exchanges reads our thread.
In many ways it's just a virtual extension of what I used to do with 1st Boston and Smith Barney in the old days-- hand out a newsletter! still doing it I guess... Ayyyyyyyy.
But with that many viewers who check in once or twice a day the thread itself multiplies
naturally. As you saw when you stepped away for a few days.. so we will keep gaining readers and we will peak out at Christmas time when I am closing the thread.
Van I hate to bust your bubble and nobody loves Van more than me that's a fact.
But the thread has over 20K unique viewers many of them professionals in the stock world. I have sent the link around to major house and hedge funds. We are viewed by the most upper upper parts of the financial system. Even the head of one of the exchanges reads our thread.
In many ways it's just a virtual extension of what I used to do with 1st Boston and Smith Barney in the old days-- hand out a newsletter! still doing it I guess... Ayyyyyyyy.
But with that many viewers who check in once or twice a day the thread itself multiplies
naturally. As you saw when you stepped away for a few days.. so we will keep gaining readers and we will peak out at Christmas time when I am closing the thread.
Van are you in on the THE PITCH--
I'll tell you why I like the concept- I feel like we have taught the children alot. And I want to encourage other folks watching to give their own ideas or pitches. And I want to show what I have to go through at The HF when I bring them a big idea.
You have to sell it. You have to believe it. You got to kick the dirt and come up with a theme.
Also I feel this way we will hold the thread to just the most interesting ideas. The market action has been so bad lately it is near impossible to buy and hold. I have tried. There just is no confidence in things continuing on their own.
This choppy action has prevented me from committing to anything. My last big buy was federal signal and that was while ago. So we need DOUBLES, we need 100% gainers. Every Pitch should come with that potential--
I'll tell you why I like the concept- I feel like we have taught the children alot. And I want to encourage other folks watching to give their own ideas or pitches. And I want to show what I have to go through at The HF when I bring them a big idea.
You have to sell it. You have to believe it. You got to kick the dirt and come up with a theme.
Also I feel this way we will hold the thread to just the most interesting ideas. The market action has been so bad lately it is near impossible to buy and hold. I have tried. There just is no confidence in things continuing on their own.
This choppy action has prevented me from committing to anything. My last big buy was federal signal and that was while ago. So we need DOUBLES, we need 100% gainers. Every Pitch should come with that potential--
Stoney entering the arena of stocks.
OCGN Ocugen, Inc.
$1.610.00 (0.00%)4:00 PM 11/18/22
NASDAQ | $USD | Post-Market: $1.63 +0.02 (+1.24%) 7:57 PM
This small bio deserves watching.
Two years ago, India’s Bharat Biotech, a leading vaccine manufacturer, jumped on a promising early study of a nasal vaccine designed at Washington University in St. Louis and negotiated to make and test doses. India recently approved the vaccine based on data that Bharat has presented to American government scientists, but not released publicly.
The vaccine has progressed more slowly in the United States. Only last month did a smaller American company, Ocugen, secure the rights to it.
$1.610.00 (0.00%)4:00 PM 11/18/22
NASDAQ | $USD | Post-Market: $1.63 +0.02 (+1.24%) 7:57 PM
This small bio deserves watching.
Two years ago, India’s Bharat Biotech, a leading vaccine manufacturer, jumped on a promising early study of a nasal vaccine designed at Washington University in St. Louis and negotiated to make and test doses. India recently approved the vaccine based on data that Bharat has presented to American government scientists, but not released publicly.
The vaccine has progressed more slowly in the United States. Only last month did a smaller American company, Ocugen, secure the rights to it.
Right Stoney...
This is coming from the guy that doesn't even understand the concept of covered calls.
Yeah, the heads of the world's top investment houses tune in daily to see your SA cut and pastes.
The clicks stayed the same while I was gone for a few days, because all the locals here are used to clicking on the thread to see what we're ranting about on any given day. When you make a post and the thread jumps to the top of the stock forum list, they have no idea if I am here or not.
And yes... until I started posting in the "Ideas for now" thread... you had less than 2K views on any of your threads that had been in existence for years. Do a search, you'll see.
You're a legend in your own mind brother.
Back to MGNX and their $60M windfall... as I pointed out, when Sanofi inked the deal with Provention back in early October, you'll notice on the same day MGNX took off from the lows around $3.
So... pretty sure it was priced in here too. You might get a little bump on momentum this week, but you won't come close to a double. If it was gonna move much, it would have Friday.